Skip to content

Kardigan

US · KARD #3042 by market cap Listed 2026
13.83 +0.34 +2.52%
Live - 5344 symbols - heartbeat 327s ago · 2026-10-07 19:54
After-hours 13.83 0.00%
Market cap
1.29B
P/B
2.10
EPS
-2.19
Reader sentiment Are you bullish or bearish on KARD?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 2.05 In line with history 52nd percentile
5-year average -1.54 · #227 of 514 in Biotechnology
P/E ratio -4.37 Expensive vs history 95th percentile
5-year average -6.80 · forward -3.49
P/S ratio --
5-year average 0.00

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Kardigan (KARD) 1.29B -4.48 2.10 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value23.69 Economic moatNone UncertaintyVery High

Trading 71.3% below Morningstar's fair value estimate.

Fair value

Kardigan Inc earns a 5-star quantitative star rating, reflecting our opinion that this share class offers a compelling opportunity for investors. The stock currently trades at a 43% discount to our quantitative fair value estimate of $23.69 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 2.2 falls in the bottom 20% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.

Alternatively, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, lies in the bottom 30% compared with global peers. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none.

By Quantitative Equity Report

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.